Too many numbers: Microarrays in clinical cancer research

Studies in History and Philosophy of Science Part C :Studies in History and Philosophy of Biological and Biomedical Sciences

Volumn 43, Issue 1, 2012, Pages 37-51

  Keating, Peter ^a   Cambrosio, Alberto ^b  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DNA MICROARRAY; GENETICS; HUMAN; MEDICAL RESEARCH; METHODOLOGY; NEOPLASM;

BIOMEDICAL RESEARCH; HUMANS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RESEARCH DESIGN;

EID: 84856644521     PISSN: 13698486     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.shpsc.2011.10.004     Document Type: Article

References (104)

1. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
2. Andreopoulos B., An A., Wang X., Schroeder M. A roadmap of clustering algorithms: Finding a match for a biomedical application. Briefings in Bioinformatics 2009, 10:297-314.
3. Baggerly K.A., Coombes K.R. Deriving chemosensitivity from cell lines: Forensic bioinformatics and reproducible research in high-throughput biology. Annals of Applied Statistics 2009, 3:1309-1334.
4. Baggerly K., Coombes K. Retraction based on data given to Duke last November, but apparently disregarded. The Cancer Letter 2010, 36(39):1. and 4-6.
5. Balmer B. Managing mapping in the Human Genome Project. Social Studies of Science 1996, 26:531-573.
6. Bammler T., Beyer R.P., Bhattacharya S., Boorman G.A., Boyles A., Bradford B.U., et al. Standardizing global gene expression analysis between laboratories and across platforms. Nature Methods 2005, 2:351-356. Members of the Toxicogenomics Research Consortium.
7. Barone, J. (2007). New tests help chemotherapy hit the mark. Discover, January; at: http://discovermagazine.com/2007/jan/genetics/.
8. Barrett T., Edgar R. Mining microarray data at NCBI's Gene Expression Omnibus (GEO). Methods in Molecular Biology 2006, 338:175-190.
9. Biganzoli E., Lama N., Ambrogi F., Antolini L., Boracchi P. Prediction of cancer outcome with microarrays. Lancet 2005, 365:1683.
10. Brazma A. Minimum Information About a Microarray Experiment (MIAME). Success, failure, challenges. The Scientific World Journal 2009, 9:420-423.
11. Brazma A., Robinson A., Cameron G., Ashburner M. One-stop shop for microarray data. Nature 2000, 403:600-700.
12. Brazma A., Hingamp P., Quackenbush J., Sherlock G., Spellman P., Stoeckert C., et al. Minimum information about a microarray experiment. Towards standards for microarray data. Nature Genetics 2001, 29:365-371.
13. Burke A. NCI creates new molecular statistics and bioinformatics section, appoints Hunter. Bioinform 1999.
14. Causton H.C., Quackenbush J., Brazma A. Microarray gene expression data analysis: A beginner's guide 2003, Blackwell, Maldon, MA.
15. Churchill G. Fundamentals of experimental design for cDNA microarrays. Nature Genetics 2002, 34(Suppl. 4):490-495.
16. Collins H.M. Changing order: Replication and induction in scientific practice 1992 [1985], University of Chicago Press, Chicago.
17. Coombes K.R., Wang J., Baggerly K.A. Microarrays: Retracing steps. Nature Medicine 2007, 13:1276-1277.
18. Correa Geyer F., Reis-Filho J.S. Microarray-based gene expression profiling as a clinical tool for breast cancer management: Are we there yet?. International Journal of Surgical Pathology 2009, 17:285-302.
19. Cui X., Hwang J.T., Qiu J., Blades N.J., Churchill G.A. Improved statistical test for differential gene expression by shrinking variance component estimates. Biostatistics 2005, 6:59-75.
20. de Ronde J., Wessels L., Wesseling J. Molecular subtyping of breast cancer: Ready to use?. Lancet 2010, 11:306-307.
21. DeMets D.L., Stormo G., Boehnke M., Louis T.A., Taylor J., Dixon D. Training of the next generation of biostatisticians: A call to action in the US. Statistics in Medicine 2006, 25:3415-3429.
22. DeRisi, J., Penland, L., & Brown, P. O. (Group 1); Bittner, M. L., Meltzner, P. S., Ray, M., Chen, Y., Su, Y. A., & Trent, J. M. (Group 2) (1996). Use of cDNA microarray to analyse gene expression patterns in human cancer. Nature Genetics, 14, 457-460.
23. Draghici S., Khatri P., Eklund A.C., Szallasi Z. Reliability and reproducibility issues in DNA microarray measurements. TRENDS in Genetics 2006, 22:101-109.
24. Dreifus, C. (2011). A conversation with the matriarch of modern cancer genetics. New York Times, February 8, D2; at: http://www.nytimes.com/2011/02/08/science/08conversation.html.
25. Dudoit S., Fridlyand J., Speed T.P. Comparison of discrimination methods for classification of tumors using DNA microarrays. Journal of the American Statistical Association 2002, 97:77-87.
26. Fan X., Shi L., Fang H., Cheng Y., Perkins R., Tong W. DNA microarrays are predictive of cancer prognosis: A re-evaluation. Clinical Cancer Research 2010, 16:629-636.
27. Fujimura J.H., Chou D.Y. Dissent in science. Styles of scientific practice and the controversy over the cause of AIDS. Social Science & Medicine 1994, 28:1017-1026.
28. Garge N., Page G.P., Spargue A.P., Gorman B.S., Allison D.B. Reproducible clusters from microarray research: Whither?. BMC Bioinformatics 2005, 6(Suppl. 2):1-11.
29. Gentleman R.C., Carey V.J., Bates D.M., Bolstad B., Dettling M., Dudoit S., et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biology 2004, 5:R80.
30. Goldberg P. Duke University suspends two clinical trials after journal paper questions assay results. The Cancer Letter 2009, 35(37):1. and 7-8.
31. Goldberg P. Duke in process to restart three trials using microarray analysis of tumors. The Cancer Letter 2010, 36(3):1. and 2-4.
32. Goldberg P. IOM review of Duke genomics trials to focus on validation, scientific criteria. The Cancer Letter 2010, 36(38):1-2.
33. Goldberg P. IOM committee will probe Duke scandal together with other 'omics' case studies. The Cancer Letter 2011, 37(1):1-8.
34. Goss Tusher V., Tibshirani R., Chu G. Significance analysis of microarrays applied to the ionizing radiation response. PNAS 2001, 98:5116-5121.
35. Hacking I. Styles of scientific reasoning. Post-analytic philosophy 1985, 145-165. Columbia University Press, New York. J. Rajchman, C. West (Eds.).
36. Hacking I. Inaugural lecture: Chair of philosophy and history of scientific concepts at the Collège de France, 16 January 2001. Economy and Society 2002, 31:1-14.
37. Hagen J.B. The origins of bioinformatics. Nature Reviews Genetics 2000, 1:231-236.
38. He Y.D., Friend S.H. Microarrays: The 21st century divining rod. Nature Medicine 2001, 7:658-659.
39. Hess K.R., Zhang W., Baggerly K.A., Stivers D.N., Coombes K.R. Microarrays: Handling the deluge of data and extracting reliable information. Trends in Biotechnology 2001, 19:463-468.
40. The fourth paradigm: Data-intensive scientific discovery 2009, Microsoft Research, Redmond. T. Hey, S. Tansley, K. Tolle (Eds.).
41. Hsu D.S., Balakumaran B.S., Acharya C.R., Vlahovic V., Walters K.S., Garman K., et al. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. Journal of Clinical Oncology 2007, 25(2007):4350-4357.
42. Ioannidis J.P.A. Microarrays and molecular research: Noise discovery?. Lancet 2005, 365:454-455.
43. Ioannidis J.P., Allison D.B., Ball C.A., Coulibaly I., Cui X., Culhane A.C., et al. Repeatability of published microarray gene expression studies. Nature Genetics 2009, 41:149-155.
44. Irizarry R.A., Warren D., Spencer F., Kim I.F., Biswal S., Frank B.C., et al. Multiple-laboratory comparison of microarray platforms. Nature Methods 2005, 2:345-349.
45. Johnson K. Natural history as stamp collecting: A brief history. Archives of Natural History 2007, 34:244-258.
46. Kahn S.D. On the future of genomic data. Science 2011, 331:728-729.
47. Keating P., Cambrosio A. Interlaboratory life: Regulating flow cytometry. The invisible industrialist: Manufacturers and the construction of scientific knowledge 1998, 250-295. Macmillan, London, New York: St. Martin's Press. J.P. Gaudillière, I. Löwy (Eds.).
48. Keating P., Cambrosio A. Biomedical platforms. Realigning the normal and the pathological in late-twentieth-century medicine 2003, MIT Press, Cambridge, MA.
49. Keating P., Cambrosio A. Cancer on trial: The rise of oncology as a new style of practice 2012, The University of Chicago Press, Chicago.
50. Kerr M.K., Churchill G.A. Statistical design and the analysis of gene expression microarray data. Genetic Research, Cambridge 2001, 77:123-128.
51. Knapen D., Vergauwen L., Laukens K., Blust R. Best practices for hybridization design in two-color microarray analysis. Trends in Biotechnology 2009, 27:406-414.
52. Kohli-Laven N., Bourret P., Keating P., Cambrosio A. Cancer clinical trials in the era of genomic signatures: Biomedical innovation, clinical utility, and regulatory-scientific hybrids" Social Studies of Science 2011, 41:487-513.
53. Koscielny S. Why most gene expression signatures of tumors have not been useful in the clinic. Science Translational Medicine 2010, 2(14):1-3.
54. Kothapalli R., Yoder S.J., Mane S., Loughran T.P. Microarray results: How accurate are they?. BMC Bioinformatics 2002, 3:22.
55. Kusch M. Hacking's historical epistemology: A critique of styles of reasoning. Studies in History and Philosophy of Science 2010, 41:158-173.
56. Larkin J.E., Frank B.C., Gavras H., Sultana R., Quackenbush J. Independence and reproducibility across microarray platforms. Nature Methods 2005, 2:337-343.
57. Leek J.T., Scharpf R.B., Bravo H.C., Simcha D., Langmead B., Johnson W.E., Geman D., Baggerly K., Irizarry R.A. Tackling the widespread and critical impact of batch effects in high-throughput data. Nature Reviews Genetics 2010, 11:733-739.
58. Lewitter, F., & Bell, G. (2010). Maximizing an experiment. Genome Technology (June); http://www.genomeweb.com/maximizing-experiment.
59. Liu X., Lee S.-C., Casella G., Peter G.F. Assessing agreement of clustering methods with gene expression microarray data. Computational Statistics and Data Analysis 2008, 52:5356-5366.
60. Lynch M. Protocols, practices, and the reproduction of technique in molecular biology. British Journal of Sociology 2002, 53:203-220.
61. MAQC-II: analyze that! (2010). Nature Biotechnology, 28, 761.
62. Marshall E. Do-it-yourself gene watching. Science 1999, 286:444-447.
63. Master J.R.W., Lakhani S.R. How diagnosis with microarrays can help cancer patients. Nature 2000, 404:921.
64. McMeekin A., Harvey M. The formation of bioinformatics knowledge markets: an 'economies of knowledge' approach. Revue d'économie Industrielle 2002, 101:47-64.
65. McMeekin A., Harvey M., Gee S. Emergent bioinformatics and newly distributed innovation processes. The economic dynamics of modern biotechnology 2004, 236-261. Oxford University Press, Oxford. M. McKelvey, J. Laage-Hellman, A. Rickne (Eds.).
66. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. Reporting recommendations for tumor marker prognostic studies (REMARK). JNCI 2005, 97:1180-1184. Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics.
67. McShane L.M., Radmacher M.D., Freidlin B., Yu R., Li M.C., Simon R. Methods for assessing the reproducibility of clustering patterns observed in analyses of microarray data. Bioinformatics 2002, 18:1462-1469.
68. Mehta T., Tanik M., Allison D. Towards sound epistemological foundations of statistical methods for high-dimensional biology. Nature Genetics 2004, 36:943-947.
69. Michiels S., Koscielny S., Hill C. Interpretation of microarray data in cancer. British Journal of Cancer 2007, 96:1155-1158.
70. Michiels S., Koscielny S., Hill C. Prediction of cancer outcome with microarrays: A multiple random validation strategy. Lancet 2005, 365:488-492.
71. Miron M., Nadon R. Inferential literacy for experimental high-throughput biology. Trends in Genetics 2006, 22:84-89.
72. Nadon R., Shoemaker J. Statistical issues with microarrays: Processing and analysis. Trends in Genetics 2002, 18:265-271.
73. NCI awards first grants for Director's Challenge. (1999). Press release, NCI Office of Cancer Communications, 3 December; at: http://rex.nci.nih.gov/massmedia/pressreleases/molec_chal_grants.html.
74. NCI's Richard Simon: The state of the art in microarray informatics. (2002). BioArray News, 10 May; at: http://www.genomeweb.com/arrays/nci-s-richard-simon-state-art-microarray-informatics.
75. Ntzani E.E., Ioannidis J.P.A. Predictive ability of DNA microarrays for cancer outcomes and correlates: An empirical assessment. Lancet 2003, 362:1439-1444.
76. Owens J. Gene expression: Do microarrays match up?. Nature Reviews Genetics 2005, 6:432-433.
77. Page G.P., Edwards J.W., Gadbury G.L., Yelisetti P., Trivedi P., Allison D.B. The PowerAtlas: A power and sample size atlas for microarray experimental design and research. BMC Bioinformatics 2006, 7:84.
78. Pawitan Y., Michiels S., Koscielny S., Gusnanto A., Ploner A. False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics 2005, 21:3017-3024.
79. Perou C.M., Jeffrey S.S., van de Rijn M., Rees C.A., Eisen M.B., Ross D.T., et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. PNAS 1999, 96:9212-9217.
80. Potti A., Nevins J.R. Reply. Nature Medicine 2007, 13:1277-1278.
81. Potti A., Dressman H.K., Bild A., Riedel R.F., Chan G., Sayer R., et al. Genomic signatures to guide the use of chemotherapeutics. Nature Medicine 2006, 12:1294-1300.
82. Pounds S., Cheng C. Improving false discovery rate estimation. Bioinformatics 2004, 20:1737-1745.
83. Pounds S., Morris S.W. Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values. Bioinformatics 2003, 19:1236-1242.
84. Quackenbush J., Irizarry R.A. Response to Shields: MIAME, we have a problem. Trends in Genetics 2006, 22:471-472.
85. Radich J. The promise and pitfalls of gene expression studies. Best Practice and Research Clinical Haematology 2009, 22:165-167.
86. Rogers S., Cambrosio A. Making a new technology work: The standardization and regulation of microarrays. Yale Journal of Biology and Medicine 2007, 80:165-178.
87. Salit M. Standards in gene expression microarray experiments. Methods in Enzymology 2006, 411:63-78.
88. Schena M., Shalon D., Davis R.W., Brown P.O. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995, 270:467-470.
89. Shields R. MIAME, we have a problem. Trends in Genetics 2006, 22:65-66.
90. Shields R. The emperor's new clothes revisited. Trends in Genetics 2006, 22:463.
91. Simon, R. (undated). Guidelines on Statistical Analysis and Reporting of DNA Microarray Studies of Clinical Outcome, PowerPoint presentation; at: http://linus.nci.nih.gov/techreport/Simon-Dos&Donts.ppt.
92. Simon R.M., Korn E.L., McShane L.M., Radmacher M.D., Wright G.W., et al. Design and analysis of DNA microarray investigations 2003, Springer, New York.
93. Simon R.M., Radmacher M.D., Dobbin K. Design of studies using DNA microarrays. Genetic Epidemiology 2002, 23:21-36.
94. Singer N. Duke suspends researcher and halts cancer studies. The New York Times 2010.
95. Stein L.D. The case for cloud computing in genome informatics. Genome Biology 2010, 11:207.
96. Strasser B.J. GenBank: Natural history in the 21st century?. Science 2008, 322:537-538.
97. Strasser B.J. The experimenter's museum: GenBank, natural history, and the moral economies of biomedicine, 1979-1982. Isis 2011, 102:60-96.
98. Thalamuthu A., Mukhopadhyay I., Zheng X., Tseng G.C. Evaluation and comparison of gene clustering methods in microarray analysis. Bioinformatics 2006, 22:2405-2412.
99. The chipping forecast. (1999). Nature Genetics, 21(Suppl. 1).
100. The chipping forecast II. (2001). Nature Genetics, 34(Suppl. 2).
101. Tuma R.S. Calls for new reporting standards, quality control in microarrays. JNCI 2010, 102:1380-1381.
102. Vance A. Data analysts captivated by R's power. New York Times 2009.
103. Vance A. R you ready for R?. New York Times 2009.
104. Winegarden N. Microarrays in cancer: Moving from hype to clinical reality. Lancet 2003, 362:1428.